Additional file 4: Figure S4. of Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases

Effect of AD0157 on MDA-MB-231/Luc+ cell migration and apoptosis. (a) Closure of the initial scratched area by MDA-MB-231/Luc+ cells after 48 h in the absence or presence of different AD0157 doses. Broken lines in pictures indicate the initial (time 0) wound edges. Scale bars represent 100 μm. (b) Graph shows the percentage of the initial cell-free area recovered by tumor cells. (c) Representative pictures showing the effect of AD0157 on MDA-MB-231/Luc+ cell chromatin condensation after 14 h of treatment. Scale bars represent 100 μm. (d) Percentages of control and AD0157-treated tumor cells with condensed chromatin (total cells were counted by using bright field). (e) Percentages of subG1, G1, and S/G2/M MDA-MB-231/Luc+ cell subpopulations analyzed by flow cytometry after AD0157 treatment. (PS 17413 kb)

AD0157对MDA-MB-231/Luc+细胞迁移与凋亡的影响。(a) 分别在添加不同剂量AD0157与未添加AD0157的培养条件下，MDA-MB-231/Luc+细胞在48小时后闭合初始划痕区域的情况；图像中的虚线代表初始时刻（0 h）的伤口边缘，标尺刻度为100 μm。(b) 统计图展示了肿瘤细胞修复的初始无细胞区域占比。(c) 代表性显微图像显示AD0157处理14小时后，对MDA-MB-231/Luc+细胞染色质凝集的影响，标尺刻度为100 μm。(d) 统计对照组与AD0157处理组中染色质凝集的肿瘤细胞占比（总细胞数通过明场成像计数）。(e) 经AD0157处理后，通过流式细胞术分析得到的MDA-MB-231/Luc+细胞亚群（subG1、G1、S/G2/M期）占比。（附注：17413 kb）